REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings > Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Four Carbocyclic Rings (e.g., Daunomycin, Etc.) Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Four Carbocyclic Rings (e.g., Daunomycin, Etc.)Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Four Carbocyclic Rings (e.g., Daunomycin, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010466 - Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML). ... 01/11/07 - 20070010465 - Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar, daunorubicin, and cytarabine. The invention is also directed to pharmaceutical formulations comprising zosuquidar, daunorubicin, and cytarabine. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML). ... 01/04/07 - 20070004653 - Stable lyophilized anthracycline glycosides The present invention provides lyophilized and stable lyophilized anthracycline glycoside salts, in particular, the hydrochloride salt. Also, the present invention provides methods of stabilizing these anthracycline glycoside salts, and methods for producing stable lyophilized anthracycline glycoside salts, such as for example the antineoplastic compound idarubicin hydrochloride, or the compounds doxorubicin ... 12/07/06 - 20060276418 - Multidrug resistant anticancer anthracyclines Daunorubicin (“DNR”) compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers. ... 11/30/06 - 20060270617 - Hki10311129, novel antibiotic, method for producting the same and the use thereof The invention relates to the novel antibiotic HKI10311129 which has a molecular weight of 1113 and the summation formula C56H75NO22. The invention also relates to a method for producing said antibiotic using the microorganism Streptomyces spec. DSM 13059, and to the use thereof as an antibacterial substance which is especially ... 11/23/06 - 20060264388 - Method for treating liver cancer by intrahepatic administration of nemorubicin The present invention relates to a treatment schedule of nemorubicin administered via the intrahepatic artery in a dosage ranging from about 100 mcg/m2 to about 800 mcg/m2 every 6 weeks to patients with a liver cancer. ... 11/09/06 - 20060252714 - Pharmaceutical compositions and methods for treating multidrug resistant cancer The invention relates to a pharmaceutical composition comprising i) ketotifen or an analog thereof and ii) a chemotherapeutic drug subject to multi-drug resistance by P-gp, such as doxorubicin or an analog thereof. The pharmaceutical composition is useful for treating cancer. The pharmaceutical composition is also useful for i) preventing or ... 11/02/06 - 20060247186 - Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer. ... 11/02/06 - 20060247185 - Stabilization of amrubicin hydrochloride A stabilized amrubicin hydrochloride composition which comprises 3 to 8 wt. % water and 92 to 97 wt. % amrubicin hydrochloride; and a method of storing amrubicin hydrochloride. ... 10/19/06 - 20060234960 - Methods and compositions for increasing the safety and efficacy of albumin-binding drugs A method is provided for increasing the safety and efficacy of albumin-binding drugs such as those used as anti-cancer, anti-infective, or anti-hypertensive drugs, or for numerous other conditions. In the preferred method, the invention modulates those drugs which bind at the IB site on human serum albumin by co-administering a ... 10/05/06 - 20060223766 - Epimerization of 4'-c bond and modification of 14-ch3-(co)-fragment in anthracyclin antibiotics A method of synthesizing R1, R2-substituted-4′ (ax. or eq.)-OH anthracyclines and their corresponding salts of Formula (1) from daunorubicin or N-Trifluoroacetyl-4-R1-derivatives of daunorubicin, wherein R1 is defined as H, OH, and 4′-HO is defined as ax[ial]. The method includes producing N-Trifluoroacetyl daunorubicin and treating the N-Trifluoroacetyldaunorubicin or N-Trifluoroacetyl-4-R1-derivatives of daunorubicin, ... 09/14/06 - 20060205684 - Method of preparing 4-r-substituted 4-demethoxydaunorubicin A method of synthesizing 4-R-substituted anthracyclines and their corresponding salts from 4-demethyldaunorubicin includes the steps of treating 4-demethyldaunorubicin with a sulfonylating agent to form 4-demethyl-4-sulfonyl-R3-daunorubicin. 4-Demethyl-4-R3-sulfonyl-daunorubicin is then subject to a reducing agent in the presence of a transition metal catalyst in a temperature range of about 30° C. to ... 09/07/06 - 20060199775 - Use of pkc-activating compounds as cardioprotectants and as apoptosis-inducing anti-tumor agents Compounds for the inducing apoptosis in cancer cells are described. The described compounds induce the translocation of protein kinase C-δ to the mitochondria and the phosphorylation of mitochondrial phospholipid scramblase 3. The compounds also provide cardioprotection through the translocation and activation of protein kinase C-ε in cardiomyocytes, thereby inhibiting apoptosis ... 07/27/06 - 20060166907 - Composition for the treatment of nasopharyngeal carcinoma and method of use thereof Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracyline. ... 07/20/06 - 20060160756 - Treatment and prevention of multi-drug resistance A method of preventing formation of multi-drug resistance (MDR) or of treating a patient that has developed or is subject to the development of MDR comprises administering a regimen comprising one or more active drugs together with one or more MDR inhibitors such that the pharmacokinetic (PK) profile of the ... 07/20/06 - 20060160755 - Neoadjuvant treatment of breast cancer Neoadjuvant treatment of inflammatory or T3 to T4 breast cancer is carried out by administering to such patients a number of cycles of chemotherapy treatment in which DPPE first is administered followed by a combination of anthracyclines and taxanes. ... 04/27/06 - 20060089317 - Treatment of metastatic breast cancer with anthracyclines, and taxanes An improved adjuvant treatment of metastatic breast cancer in which patients are administered an anthracycline chemotherapeutic agent and a taxane chemotherapeutic agent is provided in which a diphenyl compound which is a potent antagonist of histamine binding at the intracellular histamine receptor is initially administered prior to administration of the ... 03/23/06 - 20060063726 - Thermally stable crystalline epirubicin hydrochloride and method of making the same 100 ... // - 77.815 - ... // - 7.7 - ... // - 64.699 - ... // - 5.9 - ... // - 44.293 - ... // - 13.1 - ... // - 38.157 - ... // - 4.4 - ... // - 34.392 - ... // - 10.1 - ... // - 29.757 - ... // - 16.5 - ... // - 27.762 - ... // - 18.4 - ... // - 25.879 - ... // - 29.9 - ... // - 24.071 - ... // - 25.5 - ... // - 22.529 - ... // - 9.7 - ... // - 21.114 - ... // - 5 - ... // - 18.234 - ... // - 4.8 - ... // - 16.446 - ... // - 15.5 - ... // - 13.732 - ... // - 12.5 - ... // - 9.212 - ... // - 9.8 - ... // - 5.236 - ... // - 2Θ - ... 01/19/06 - 20060014708 - 2,6-diaminopyridine derivatives wherein R1 and R2 are as defined below, are disclosed. These compounds inhibit cyclin-dependent kinases. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing ... 01/05/06 - 20060003950 - Method of treating prostatic diseases using a combination of vitamin d analogues and other agents The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced ... 01/05/06 - 20060003949 - Freeze-dried preparation of stabilized anthracycline compound The present invention provides a lyophilized preparation of amrubicin, which contains L-cysteine or a salt thereof and has a water content of 0 to about 4% by weight within the preparation, and is stable even in a long-term storage, and further provides a method for production of said preparation. Said ... 12/22/05 - 20050282759 - Injectable ready-to-use solutions containing an antitumor anthracycline glycoside A sealed glass container containing therein a stable, injectable, sterile, pyrogen-free doxorubicin anti-tumor composition in a solution which consists essentially of a physiologically acceptable salt of doxorubicin dissolved in a physiologically acceptable solvent therefore, wherein said solution has not been reconstituted from a lyophilizate, and wherein said solution has a ... 10/13/05 - 20050227932 - Combinational therapy involving a small molecule inhibitor of the mdm2: p53 interaction The present invention is directed to a combinational therapy for treating cancer or other cell proliferative diseases. Such a therapy combines the use of radiation therapy or chemotherapy with the use of a small molecule inhibitor of the MDM2: p53 interaction. ... 10/06/05 - 20050222054 - Combination comprising a cdk inhibitor and doxorubicin A first aspect of the invention relates to a combination comprising a CDK inhibitor and doxorubicin. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and doxorubicin as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the ... 09/22/05 - 20050209174 - Molecular conjugates for use in treatment of cancer wherein R1 is a de-hydroxyl or de-amino moiety respectively of a hydroxyl-bearing or amino-bearing biologically active molecule or an analog or derivative thereof, and Z is —O— or —NH—, respectively, Y is a straight or branched alkyl having 1 to 20 carbons that may be optionally substituted with one or ... 09/22/05 - 20050209173 - Neurodegenerative protein aggregation inhibition methods and compounds Methods and compositions are provided for reducing aggregation of neurodegenerative proteins associated with neurotoxicity or other proteins. The compounds comprise a first domain or targeting element for binding to the target proteins linked to a second domain or recruiting element that binds to an aggregation inhibiting protein, e.g. a prolyl ... 09/01/05 - 20050192235 - Compositions and methods for treating or preventing diseases of body passageways The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics. ... 08/25/05 - 20050187170 - Enhancing the efficiency of rna polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors The present invention relates generally to pharmaceutical compositions useful to treat viral diseases. The present invention relates particularly RNA polymerase inhibitors and inosine monophosphate dehydrogenase (IMPDH) inhibitors such as mycophenolate compounds. ... 07/07/05 - 20050148521 - Anti-cancer combination and use thereof The present invention relates to the surprising discovery that the combination of several agents, each well known for its established role in treating cancer, inflammation, hemostasis, bone resorption or serving as a solubilizing vehicle, results in a synergistic anti-cancer composition. Furthermore, the combination of at least three agents allows the ... 06/02/05 - 20050119196 - Remedies for lung cancer By using a combination of amrubicin or a pharmaceutically acceptable salt thereof with another medicament for treating lung cancer (irinotecan, vinorelbine, gemcitabine, etc.), it is intended to provide medicaments for treating lung cancer having an improved antitumor therapeutic effect on lung cancer and reduced side effects. Lung cancer can be ... ### FreshPatents.com Support |